T-cell non-Hodgkin lymphoma
diseaseOn this page
Also known as non-Hodgkin's T-cell lymphomaT cell lymphomaT-cell and NK-cell non-Hodgkin lymphomaT-cell and NK-cell non-Hodgkin's lymphomaT-cell lymphomaT-cell NHLT-cell non-Hodgkin's lymphoma
Summary
T-cell non-Hodgkin lymphoma (MONDO:0015760) is a cancer (an umbrella term covering 9 Mondo subtypes) and 235 clinical trials. Top therapeutic interventions include brentuximab vedotin, cytarabine, and romidepsin. A subtype of non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Umbrella term: 9 Mondo subtypes
- Clinical trials: 235
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.99 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | T-cell non-Hodgkin lymphoma |
| Mondo ID | MONDO:0015760 |
| MeSH | D016399 |
| Orphanet | 171918 |
| DOID | DOID:0081312 |
| NCIT | C3466 |
| SNOMED CT | 109978004 |
| UMLS | C0079772 |
| MedGen | 86957 |
| GARD | 0020133 |
| MedDRA | 10042971 |
| Is cancer (heuristic) | yes |
Also known as: non-Hodgkin’s T-cell lymphoma · T cell lymphoma · T-cell and NK-cell non-Hodgkin lymphoma · T-cell and NK-cell non-Hodgkin’s lymphoma · T-cell lymphoma · T-cell NHL · T-cell non-Hodgkin lymphoma · T-cell non-Hodgkin’s lymphoma
Data availability: 27 cell lines.
Disease family
This is a subtype of non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › non-Hodgkin lymphoma › T-cell non-Hodgkin lymphoma
Related subtypes (9): lymphoblastic lymphoma, lymphosarcoma, acute lymphoblastic leukemia, lymphoma, non-Hodgkin, familial, B-cell non-Hodgkin lymphoma, lung non-Hodgkin lymphoma, ocular adnexal lymphoma, large-cell immunoblastic lymphoma, gastric non-hodgkin lymphoma
Subtypes (9): mature T-cell and NK-cell non-Hodgkin lymphoma, primary cutaneous T-cell lymphoma, CD4+/CD56+ hematodermic neoplasm, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, T-lymphoblastic lymphoma, Nodal T-follicular helper cell lymphoma, follicular type, monomorphic epitheliotropic intestinal T-cell lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
6 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Belinostat | Approved (phase 4) |
| Bexarotene | Approved (phase 4) |
| Methoxsalen | Approved (phase 4) |
| Pralatrexate | Approved (phase 4) |
| Romidepsin | Approved (phase 4) |
| Vorinostat | Approved (phase 4) |
| Tucidinostat | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Busulfan, Doxorubicin, Etoposide, Filgrastim, Fludarabine, Gemcitabine, Lenalidomide, Melphalan, Palifermin, Plerixafor, Prednisone, Vincristine.
Clinical trials & evidence
Clinical trials
Clinical trials: 235.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 83 |
| PHASE1 | 70 |
| PHASE1/PHASE2 | 34 |
| Not specified | 34 |
| EARLY_PHASE1 | 6 |
| PHASE3 | 4 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01501136 | PHASE4 | UNKNOWN | Treatment of Natural Killer/T Cell Lymphoma-I/II |
| NCT01501149 | PHASE4 | UNKNOWN | Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ |
| NCT05442554 | PHASE4 | COMPLETED | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
| NCT05700448 | PHASE3 | NOT_YET_RECRUITING | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma |
| NCT00725231 | PHASE3 | UNKNOWN | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP |
| NCT00877656 | PHASE2/PHASE3 | COMPLETED | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma |
| NCT01777152 | PHASE3 | COMPLETED | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas |
| NCT05075460 | PHASE3 | UNKNOWN | Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma |
| NCT02859402 | PHASE2 | RECRUITING | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas |
| NCT02978625 | PHASE2 | ACTIVE_NOT_RECRUITING | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
| NCT03628612 | PHASE2 | ENROLLING_BY_INVITATION | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells |
| NCT04414163 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type |
| NCT04752826 | PHASE1/PHASE2 | RECRUITING | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) |
| NCT05092451 | PHASE1/PHASE2 | RECRUITING | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances |
| NCT05230680 | PHASE1/PHASE2 | RECRUITING | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) |
| NCT05313243 | PHASE2 | RECRUITING | Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma |
| NCT05996185 | PHASE2 | RECRUITING | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma |
| NCT06151106 | PHASE2 | RECRUITING | Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma |
| NCT06390319 | PHASE2 | RECRUITING | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) |
| NCT06406556 | PHASE2 | RECRUITING | Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL |
| NCT06420076 | PHASE1/PHASE2 | RECRUITING | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells |
| NCT06756308 | PHASE2 | RECRUITING | A Study of Enasidenib in People With T-Cell Lymphoma |
| NCT06824883 | PHASE2 | RECRUITING | Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma |
| NCT06874946 | PHASE1/PHASE2 | RECRUITING | Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL |
| NCT06925464 | PHASE1/PHASE2 | RECRUITING | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas |
| NCT06966154 | PHASE1/PHASE2 | RECRUITING | A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL |
| NCT07022964 | PHASE1/PHASE2 | RECRUITING | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas |
| NCT07106723 | PHASE2 | RECRUITING | Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL |
| NCT07117305 | PHASE1/PHASE2 | NOT_YET_RECRUITING | CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation |
| NCT07225985 | PHASE1/PHASE2 | RECRUITING | Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma |
| NCT07356245 | PHASE2 | RECRUITING | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma |
| NCT07380984 | PHASE2 | RECRUITING | PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL |
| NCT07385989 | PHASE2 | NOT_YET_RECRUITING | Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma |
| NCT07496229 | PHASE1/PHASE2 | RECRUITING | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) |
| NCT07502768 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma |
| NCT07554482 | PHASE2 | NOT_YET_RECRUITING | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma |
| NCT00006251 | PHASE1/PHASE2 | COMPLETED | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
| NCT00040846 | PHASE2 | COMPLETED | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
| NCT00049504 | PHASE2 | COMPLETED | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
| NCT00072514 | PHASE2 | COMPLETED | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BRENTUXIMAB VEDOTIN | 4 | 5 |
| CYTARABINE | 4 | 5 |
| ROMIDEPSIN | 4 | 5 |
| BENDAMUSTINE | 4 | 4 |
| ALEMTUZUMAB | 4 | 3 |
| DUVELISIB | 4 | 3 |
| PEGASPARGASE | 4 | 3 |
| SUGEMALIMAB | 4 | 3 |
| 2-MERCAPTOETHANESULFONIC ACID | 4 | 2 |
| BELINOSTAT | 4 | 2 |
| BETAMETHASONE | 4 | 2 |
| CEMIPLIMAB | 4 | 2 |
| DEXAMETHASONE | 4 | 2 |
| GEMCITABINE | 4 | 2 |
| IFOSFAMIDE | 4 | 2 |
| PANOBINOSTAT | 4 | 2 |
| PLERIXAFOR | 4 | 2 |
| TAZEMETOSTAT | 4 | 2 |
| VORINOSTAT | 4 | 2 |
| AVELUMAB | 4 | 1 |
| BASILIXIMAB | 4 | 1 |
| CALASPARGASE PEGOL | 4 | 1 |
| CARFILZOMIB | 4 | 1 |
| CISPLATIN | 4 | 1 |
| CLOFARABINE | 4 | 1 |
| DEFERASIROX | 4 | 1 |
| DEXAMETHASONE ACETATE | 4 | 1 |
| DEXRAZOXANE | 4 | 1 |
| DEXRAZOXANE HYDROCHLORIDE | 4 | 1 |
| ENASIDENIB | 4 | 1 |
Related Atlas pages
- Drugs: Brentuximab Vedotin, Cytarabine, Romidepsin, Bendamustine, Alemtuzumab, Duvelisib, Pegaspargase, Sugemalimab, 2-MERCAPTOETHANESULFONIC ACID, Belinostat, Betamethasone, Cemiplimab, Dexamethasone, Gemcitabine, Ifosfamide, Panobinostat, Plerixafor, Tazemetostat, Vorinostat, Avelumab, Basiliximab, Calaspargase Pegol, Carfilzomib, Cisplatin, Clofarabine, Deferasirox, Dexamethasone Acetate, Dexrazoxane, Enasidenib